Sugi Predict

Sugi Predict / Compounds / SCHEMBL2676372

SCHEMBL2676372

SCHEMBL2676372

Fc1cnccc1Oc1ccc2nc(NCC3CCCCC3)sc2c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 9/20 0.47
▸ RAB9A P51151 3/20 0.42
▸ CD274 Q9NZQ7 1/20 0.42
▸ USP30 Q70CQ3 2/20 0.41
▸ NPC1 O15118 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ PKM P14618 1/20 0.39
▸ PI4KA P42356 2/20 0.39
▸ PIK3CG P48736 2/20 0.39
▸ PI4KB Q9UBF8 2/20 0.39
▸ GALR1 P47211 1/20 0.39
▸ PIK3CD O00329 1/20 0.39
▸ CSNK1D P48730 1/20 0.39
▸ PDGFRB P09619 1/20 0.38
▸ KIT P10721 1/20 0.38
▸ PDGFRA P16234 1/20 0.38
▸ FLT3 P36888 1/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ KDM1A O60341 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4372980 0.89 CSF1R (0.47) CSF1RRAB9ACD274USP30NPC1
SCHEMBL2846117 0.87 CSF1R (0.54) CSF1RRAB9ACD274USP30NPC1
SCHEMBL14396469 0.85 CSF1R (0.62) CSF1RRAB9ANPC1MAPTPKM
SCHEMBL2677488 0.85 CSF1R (0.55) CSF1RRAB9ACD274USP30NPC1
SCHEMBL2676507 0.84 MET (0.45) CSF1RRAB9AUSP30NPC1MAPT
SCHEMBL2676555 0.82 USP30 (0.46) CSF1RRAB9AUSP30NPC1MAPT
SCHEMBL2676960 0.81 USP30 (0.45) CSF1RRAB9AUSP30NPC1MAPT
SCHEMBL2840848 0.81 CSF1R (0.47) CSF1RRAB9ANPC1MAPTPKM
SCHEMBL2677672 0.80 MET (0.46) CSF1RRAB9ANPC1MAPTPKM
SCHEMBL2676586 0.80 CSF1R (0.58) CSF1RPDGFRBKITPDGFRAFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710048-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2014-04-29 — — US disclosed
US-8710048-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2014-04-29 — — US disclosed
US-8710048-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2014-04-29 — — US disclosed
US-20120225861-A1 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2012-09-06 — — US disclosed
US-20120225861-A1 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2012-09-06 — — US disclosed
US-20120225861-A1 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2012-09-06 — — US disclosed
US-8173689-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2012-05-08 — — US disclosed
US-8173689-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2012-05-08 — — US disclosed
US-8173689-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2012-05-08 — — US disclosed
US-20100280006-A1 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS AG (CH) 2010-11-04 — — US disclosed
US-7553854-B2 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-06-30 — — US disclosed
US-20080045528-A1 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING NOVARTIS AG 2008-02-21 — — US disclosed
US-20080045528-A1 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING NOVARTIS AG 2008-02-21 — — US disclosed
US-20080045528-A1 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING NOVARTIS AG 2008-02-21 — — US disclosed
WO-2007121484-A2 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING NOVARTIS AG (CH) 2007-10-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225861-A1 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling CSF1R, CSF3R, FLT3 CSF1R 1/4885RAB9A 2177/4885CD274 320/4885
US-20100280006-A1 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling CSF1R, CSF3R, FLT3 CSF1R 1/4885RAB9A 2177/4885CD274 320/4885
US-20080045528-A1 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING CSF1R, CSF3R, FLT3 CSF1R 1/4885RAB9A 2177/4885CD274 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.